ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

Better event-free survival outcomes seen for durvalumab plus FLOT versus FLOT alone in phase 3 randomized trial
stomach
Adobe
Medically Reviewed By:
Farrokh Sohrabi, M.D.
Published on
Updated on
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com